Clinical trial : hepatitis B virus genotype and a combination of end‐of‐treatment biomarkers predict severe flares after nucleos(t)ide analogue cessation

Source
Alimentary pharmacology and therapeutics - ISSN 0269-2813- (2025) p. 1-10
Author(s)
    Arno Furquim d'Almeida, Axelle Vanderlinden, Stefan Bourgeois, Jean‐Pierre Mulkay, Thomas Sersté, Mathieu Struyve, Baro Deressa, Dirk Sprengers, Marie de Vos, Jos Callens, Bao Shihao, Hendrik Reynaert, Pierre Deltenre, Filip Janssens, Sergio Negrin‐Dastis, Peter Stärkel, Hans Orlent, Guy Van Roey, Xavier Verhelst, Christophe Moreno, Jean Delwaide, Christophe Van Steenkiste, Wim Verlinden, Isabelle Colle, Marie‐Laure Plissonnier, Benoît Kabamba Mukadi, Barbara Testoni, Fabien Zoulim, Veerle Matheeussen, Thomas Vanwolleghem